Adrenaline autoinjector is underprescribed in typical cold urticaria patients
Research output: Contribution to journal › Letter › Research › peer-review
Documents
- Fulltext
Final published version, 733 KB, PDF document
Original language | English |
---|---|
Journal | Allergy: European Journal of Allergy and Clinical Immunology |
Volume | 77 |
Issue number | 7 |
Pages (from-to) | 2224-2229 |
ISSN | 0105-4538 |
DOIs | |
Publication status | Published - 2022 |
Bibliographical note
Funding Information:
M. Bizjak has been a speaker and served on advisory boards for Novartis, outside the submitted work. S. F. Thomsen reports grants and non‐financial support from Novartis, Sanofi, UCB, LEO Pharma, and Janssen, outside the submitted work. D. Fomina received honoraria from Novartis, Shire, Behring CSL and Sanofi, outside the submitted work. E. Borzova received honoraria for educational lectures from Novartis and Sanofi and research funding from GSK, outside the submitted work. K. Kulthanan reports grants from Novartis and received honoraria from Menarini and Takeda, outside the submitted work. R. Meshkova received honoraria from Novartis, outside the submitted work. S. Altrichter reports grants and personal fees from Astra‐Zeneca, grants from Allakos, personal fees from Novartis, non‐financial support from Moxie, grants from CSL Behring, grants from LEO Pharma, outside the submitted work. A. Bauer reports grants, personal fees and other from Novartis, personal fees and other from LEO Pharma, grants, personal fees and other from Sanofi/Regeneron, other from Amgen, other from Lilly, other from AbbVie, personal fees from Takeda, other from Pharvaris, outside the submitted work. C. Costa reports personal fees from Novartis, AstraZeneca, Menarini, Leti and Bial, outside the submitted work. R. Fachini Criado reports personal fees from Novartis, Takeda, Abbvie and Sanofi, outside the submitted work. L.F. Felipe Ensina reports personal fees from Novartis, Sanofi, Abbvie and Takeda, outside the submitted work. A.M. Giménez‐Arnau reports grants and personal fees from Uriach, other from Genentech, grants, personal fees and other from Novartis, grants and personal fees from GSK, personal fees from Sanofi/Regeneron, personal fees from Amgen, personal fees from Thermo Fisher, grants from Instituto Carlos III, personal fees from LEO Pharma, personal fees from Almirall and personal fees from Avene, outside the submitted work. M. Gonçalo has been a speaker and/or advisor for Abbie, LEO Phama, Lilly, Novartis, Pfizer, Sanofi and Takeda, outside the submitted work. J.G. Holm has been a speaker for Novartis, outside the submitted work. E. Kocatürk reports personal fees from Novartis, Sanofi and Menarini, outside the submitted work. M. Makris reports personal fees from Novartis, Chiesi Hellas, AstraZeneca, Pfizer, GSK and Menarini, outside the submitted work. S. Valle reports personal fees from Novartis, Takeda, CSL Behring and Astra‐Zeneca outside the submitted work. N. Wagner is or recently was a speaker and/or advisor for and/or has received research funding or is/was involved in clinical trials of/from ALK‐Abelló, Novartis Pharma GmbH, Allergopharma GmbH &Co KG, Sanofi‐Aventis Deutschland GmbH, Shire/Takeda, Blueprint, Abbvie GmbH & Co KG. P. Xepapadaki reports personal fees from Uriach, Novartis, Nestle and Nutricia, outside the submitted work. M. Mauer is or recently was a speaker and/or advisor for and/or has received research funding from Allakos, Aralez, ArgenX, AstraZeneca, Celldex, Centogene, CSL Behring, FAES, Genentech, GIInnovation, Innate Pharma, Kyowa Kirin, LEO Pharma, Lilly, Menarini, Moxie, MSD, Novartis, Roche, Sanofi/Regeneron, Third HarmonicBio, UCB, and Uriach, outside the submitted work. All other authors have no conflict of interest within the scope of the submitted work.
- adrenaline autoinjector, cold urticaria, COLD-CE, cold-induced anaphylaxis
Research areas
ID: 329414612